Except for thrombocytopenia, the common adverse events include hepatotoxicity (42.87 and 37.7% for AST and ALT, respectively), neutropenia (14.5%), hypokalemia (9.4%), and anemia (38%) (23). This evidence concerns the gene GPT and anemia.